Page 16 - Cipla
Cipla board approves reappointment of Umang Vohra as MD & Global CEO
Pharma major Cipla on Tuesday said its board hasapproved the re-appointment of Umang Vohra as the Managing Director and Global CEO of the company for a further period of five years. The board of directorshas considered and approved the re-appointment ofUmang Vohra, Managing Director, designated as 'Managing Director and Global Chief ExecutiveOfficer' of the company, for a further period of five years w.e.f. April 1, 2021 to March 31,2026, Cipla said in a regulatory filing. Vohra had joined Cipla in 2015 and has been the MD & Global CEO of the company since September 1, 2016, it added. "As Cipla's MD & GCEO, Vohra's priorities have been Cipla's strategic growth, defining and executing Cipla's roadmap to maintain momentum in home markets whilst strengthening its presence in other regions, consolidating its core focus areas, augmenting capability, and building the right organisation," the filing said. After gaining degrees in engineering, marketing and finance, Vohraworked with ..
 "Cipla board approves reappointment of Umang Vohra as MD & Global CEO")
Cipla liquidates wholly-owned unit as part of internal reorganisation
Drug major Cipla on Saturday said it has voluntarily liquidated a wholly-owned step-down subsidiary.
 "Cipla liquidates wholly-owned unit as part of internal reorganisation")
Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand
Cipla stock went up by almost 3 per cent on Tuesday
 "Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand")
Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand
Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.
Cipla receives USFDA nod for nasal spray for treating migraine attacks
Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks
Cipla plans to double share from consumer health business in 5 years
Transitioning brands from prescription and trade generics to over-the-counter
Domestic drug market growth slows top 4.5% in January, some therapies drag
Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet
 "Domestic drug market growth slows top 4.5% in January, some therapies drag")
Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs
At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index
 "Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs")
Cipla's net profit zooms 113% in December quarter; revenue up 18%
The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.
Stocks to watch: TCS, Wipro, Avenue Supermarts, Tata Steel, Vedanta, Cipla
Bharti Airtel announced the appointment of Pradipt Kapoor as its Chief Information Officer
 "Stocks to watch: TCS, Wipro, Avenue Supermarts, Tata Steel, Vedanta, Cipla")
Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost
Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities
Cipla recalls over 5.8 lakh packets of gastric ulcer treatment drug in US
Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration.
Trading calls by Ajit Mishra of Religare Broking: Buy Cipla, Eicher Motors
Eicher Motors' stock has been witnessing profit taking for the last one month, and is likely to see a gradual recovery from hereon
 "Trading calls by Ajit Mishra of Religare Broking: Buy Cipla, Eicher Motors")
Nifty outlook & trading ideas by Vinay Rajani of HDFC Securities
Upside target for Nifty is seen at 14,300 odd levels, which happens to be the 138.2 per cent Fibonacci retracement of the downswing seen from 12,430 to 7,511
 "Nifty outlook & trading ideas by Vinay Rajani of HDFC Securities")
Cipla rallies 5% after settling litigation with Bristol Myers in US
Bristol Myers (Celgene) will provide Cipla with a license to sell generic volume-limited amounts of gRevlimid capsules in the US sometime after March 2022, subject to regulatory approval
 "Cipla rallies 5% after settling litigation with Bristol Myers in US")
Cipla settles blood cancer drug litigation with Bristol Myers in US
As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved
 "Cipla settles blood cancer drug litigation with Bristol Myers in US")
Chronic portfolio may help Cipla sustain growth outperformance in near term
Margin gains in the September quarter too are expected to continue
November domestic pharma sales grow just 1% after strong show last month
Oct growth rate was 9.6%; Most big corporates saw volumes drop in November
Top headlines: Passenger vehicles sales dip; Finance Commission report out
The Bombay High Court refused to grant interim bail to TV journalist Arnab Goswami.
 "Top headlines: Passenger vehicles sales dip; Finance Commission report out")
Demand for Covid-19 drug Remdesivir rising sharply in India, says Cipla
Cipla's version, Cipremi, was commercially launched in July and costs just above $50 per 100 mg vial
 "Demand for Covid-19 drug Remdesivir rising sharply in India, says Cipla")
